213 related articles for article (PubMed ID: 32312805)
41. Effects of Adolescent Cannabinoid Self-Administration in Rats on Addiction-Related Behaviors and Working Memory.
Kirschmann EK; Pollock MW; Nagarajan V; Torregrossa MM
Neuropsychopharmacology; 2017 Apr; 42(5):989-1000. PubMed ID: 27582345
[TBL] [Abstract][Full Text] [Related]
42. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.
Castelli MP; Paola Piras A; D'Agostino A; Pibiri F; Perra S; Gessa GL; Maccarrone M; Pistis M
Eur J Pharmacol; 2007 Nov; 573(1-3):11-9. PubMed ID: 17644084
[TBL] [Abstract][Full Text] [Related]
43. WIN-55,212-2 chronically implanted into the CA3 region of the dorsal hippocampus impairs learning: a novel method for studying chronic, brain-area-specific effects of cannabinoids.
Barna I; Soproni K; Arszovszki A; Csabai K; Haller J
Behav Pharmacol; 2007 Sep; 18(5-6):515-20. PubMed ID: 17762520
[TBL] [Abstract][Full Text] [Related]
44. Prospects for cannabinoid therapies in viral encephalitis.
Solbrig MV; Fan Y; Hazelton P
Brain Res; 2013 Nov; 1537():273-82. PubMed ID: 24021420
[TBL] [Abstract][Full Text] [Related]
45. Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist.
Tsou K; Lowitz KA; Hohmann AG; Martin WJ; Hathaway CB; Bereiter DA; Walker JM
Neuroscience; 1996 Feb; 70(3):791-8. PubMed ID: 10627219
[TBL] [Abstract][Full Text] [Related]
46. Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex.
Oropeza VC; Page ME; Van Bockstaele EJ
Brain Res; 2005 Jun; 1046(1-2):45-54. PubMed ID: 15927549
[TBL] [Abstract][Full Text] [Related]
47. Maternal exposure to the CB1 cannabinoid agonist WIN 55212-2 produces robust changes in motor function and intrinsic electrophysiological properties of cerebellar Purkinje neurons in rat offspring.
Shabani M; Hosseinmardi N; Haghani M; Shaibani V; Janahmadi M
Neuroscience; 2011 Jan; 172():139-52. PubMed ID: 20969930
[TBL] [Abstract][Full Text] [Related]
48. Lithium attenuates cannabinoid-induced dependence in the animal model: involvement of phosphorylated ERK1/2 and GSK-3β signaling pathways.
Rahimi HR; Dehpour AR; Mehr SE; Sharifzadeh M; Ghahremani MH; Razmi A; Ostad SN
Acta Med Iran; 2014; 52(9):656-63. PubMed ID: 25325202
[TBL] [Abstract][Full Text] [Related]
49. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons.
Auclair N; Otani S; Soubrie P; Crepel F
J Neurophysiol; 2000 Jun; 83(6):3287-93. PubMed ID: 10848548
[TBL] [Abstract][Full Text] [Related]
50. Cannabinoid-induced increase in relapse-like drinking is prevented by the blockade of the glycine-binding site of N-methyl-D-aspartate receptors.
Alén F; Santos A; Moreno-Sanz G; González-Cuevas G; Giné E; Franco-Ruiz L; Navarro M; López-Moreno JA
Neuroscience; 2009 Jan; 158(2):465-73. PubMed ID: 18977415
[TBL] [Abstract][Full Text] [Related]
51. WIN 55,212-2-induced reduction of cocaine hyperlocomotion: possible inhibition of 5-HT(3) receptor function.
Przegaliński E; Göthert M; Frankowska M; Filip M
Eur J Pharmacol; 2005 Jul; 517(1-2):68-73. PubMed ID: 15961074
[TBL] [Abstract][Full Text] [Related]
52. Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55,212-2.
Schneider M; Drews E; Koch M
Behav Pharmacol; 2005 Sep; 16(5-6):447-54. PubMed ID: 16148450
[TBL] [Abstract][Full Text] [Related]
53. Behavioral effects of chronic WIN 55,212-2 administration during adolescence and adulthood in mice.
Johnson KR; Boomhower SR; Newland MC
Exp Clin Psychopharmacol; 2019 Aug; 27(4):348-358. PubMed ID: 31120283
[TBL] [Abstract][Full Text] [Related]
54. Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test.
Yoon MH; Choi JI
Anesthesiology; 2003 Sep; 99(3):701-7. PubMed ID: 12960556
[TBL] [Abstract][Full Text] [Related]
55. Long-term reduction of brain-derived neurotrophic factor levels and signaling impairment following prenatal treatment with the cannabinoid receptor 1 receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1- naphthalenylmethanone.
Maj PF; Collu M; Fadda P; Cattaneo A; Racagni G; Riva MA
Eur J Neurosci; 2007 Jun; 25(11):3305-11. PubMed ID: 17552998
[TBL] [Abstract][Full Text] [Related]
56. Altered attention and prefrontal cortex gene expression in rats after binge-like exposure to cocaine during adolescence.
Black YD; Maclaren FR; Naydenov AV; Carlezon WA; Baxter MG; Konradi C
J Neurosci; 2006 Sep; 26(38):9656-65. PubMed ID: 16988036
[TBL] [Abstract][Full Text] [Related]
57. Inverse relationship of cannabimimetic (R+)WIN 55, 212 on behavior and seizure threshold during the juvenile period.
Rudenko V; Rafiuddin A; Leheste JR; Friedman LK
Pharmacol Biochem Behav; 2012 Jan; 100(3):474-84. PubMed ID: 22019959
[TBL] [Abstract][Full Text] [Related]
58. Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels.
Ferraro L; Tomasini MC; Cassano T; Bebe BW; Siniscalchi A; O'Connor WT; Magee P; Tanganelli S; Cuomo V; Antonelli T
J Neurosci Res; 2001 Oct; 66(2):298-302. PubMed ID: 11592127
[TBL] [Abstract][Full Text] [Related]
59. WIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid β1-42 effects on astrocytes in primary culture.
Aguirre-Rueda D; Guerra-Ojeda S; Aldasoro M; Iradi A; Obrador E; Mauricio MD; Vila JM; Marchio P; Valles SL
PLoS One; 2015; 10(4):e0122843. PubMed ID: 25874692
[TBL] [Abstract][Full Text] [Related]
60. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
